Filter Results
:
(632)
Show Results For
-
All HBS Web
(632)
- People (2)
- News (54)
- Research (440)
- Events (2)
- Multimedia (6)
- Faculty Publications (391)
Show Results For
-
All HBS Web
(632)
- People (2)
- News (54)
- Research (440)
- Events (2)
- Multimedia (6)
- Faculty Publications (391)
- 2015
- Working Paper
Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
By: Pierre Azoulay, Joshua S. Graff Zivin, Danielle Li and Bhaven N. Sampat
We quantify the impact of scientific grant funding at the National Institutes of Health (NIH) on patenting by pharmaceutical and biotechnology firms. Our paper makes two contributions. First, we use newly constructed bibliometric data to develop a method for flexibly...
View Details
Keywords:
Economics Of Science;
Patenting;
Academic Reserach;
NIH;
Knowledge Spillovers;
Patents;
Research;
Government and Politics
Azoulay, Pierre, Joshua S. Graff Zivin, Danielle Li, and Bhaven N. Sampat. "Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules." Harvard Business School Working Paper, No. 16-056, October 2015.
- May 2006 (Revised June 2006)
- Case
Codon Devices
By: Joseph B. Lassiter III and David Kiron
In December 2005, 40-year-old John Danner was about to make his first presentation to the board of directors of Codon Devices, a one-year-old biotechnology start-up based in Cambridge, Massachusetts. After a month as the company's CEO, Danner was prepared to lay out...
View Details
Keywords:
Strategic Planning;
Venture Capital;
Intellectual Property;
Governing and Advisory Boards;
Genetics;
Competitive Advantage;
Science-Based Business;
Business Startups;
Growth and Development Strategy;
Biotechnology Industry;
Cambridge
Lassiter, Joseph B., III, and David Kiron. "Codon Devices." Harvard Business School Case 806-198, May 2006. (Revised June 2006.)
- March 1996
- Case
Erox Corporation: Leverage Marketing
Erox Corp. is a biotechnology start-up that creates products containing synthetic human pheromones. It was founded in 1989, went public in 1993, and brought in a turnaround team in 1994. Sales ramped from $110,000 in 1993 to over $1 million in 1994, with prospects for...
View Details
Kosnik, Thomas J. "Erox Corporation: Leverage Marketing." Harvard Business School Case 596-046, March 1996.
- February 2003
- Article
Which Ties Matter When? The Contingent Effects of Interorganizational Partnerships on IPO Success
By: Ranjay Gulati and M. Higgins
This paper investigates the contingent value of interorganizational relationships at the time of a young firm's initial public offering (IPO). We compare the signaling value to young firms of having ties with two types of interorganizational partnerships: endorsement...
View Details
Keywords:
Interorganizatonal Relationships;
Networks;
Venture Capital;
Initial Public Offering;
Entrepreneurship;
Biotechnology Industry
Gulati, Ranjay, and M. Higgins. "Which Ties Matter When? The Contingent Effects of Interorganizational Partnerships on IPO Success." Strategic Management Journal 24, no. 2 (February 2003): 127–144.
- December 2006 (Revised October 2007)
- Case
Monsanto: Realizing Biotech Value in Brazil
By: David E. Bell and Mary L. Shelman
In 2003, Monsanto's patented "Roundup Ready" technology was used illegally on 70-80% of the soybean area in southern Brazil. Under pressure from U.S. soybean growers, who were paying to license the technology, the firm implemented an innovative delivery-based...
View Details
Keywords:
Plant-Based Agribusiness;
Patents;
Lawfulness;
Emerging Markets;
Product Development;
Biotechnology Industry;
Biotechnology Industry;
Brazil
Bell, David E., and Mary L. Shelman. "Monsanto: Realizing Biotech Value in Brazil." Harvard Business School Case 507-018, December 2006. (Revised October 2007.)
- Research Summary
3. Emergence and Early Growth of a New Venture in an Unfriendly Environment: The Role of a Business Group
Abstract: How can an established organization ease the emergence and early growth of a new venture in an unfriendly environment? To answer this question, I describe and analyze the foundation and early life of two biotechnology start-ups at the... View Details
- February 2021
- Case
Digital Manufacturing at Amgen
By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This case discusses efforts made by biotechnology (biotech) company Amgen to introduce digital technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics—or therapeutics made from living cells—is...
View Details
Keywords:
Digital Technologies;
Change;
Change Management;
Decision Making;
Cost vs Benefits;
Decisions;
Information;
Analytics and Data Science;
Innovation and Invention;
Innovation and Management;
Innovation Leadership;
Innovation Strategy;
Technological Innovation;
Jobs and Positions;
Knowledge;
Leadership;
Organizational Culture;
Science;
Strategy;
Information Technology;
Technology Adoption;
Biotechnology Industry;
Biotechnology Industry;
United States;
California;
Puerto Rico;
Rhode Island
Greenstein, Shane, Kyle R. Myers, and Sarah Mehta. "Digital Manufacturing at Amgen." Harvard Business School Case 621-008, February 2021.
- March 1992
- Case
Amgen, Inc.: Planning the Unplannable
By: Nitin Nohria
By the early 1990s, Amgen--a pharmaceutical company started little over a decade ago as Applied Molecular Genetics--was within range of becoming a billion-dollar company. With two extremely successful biotechnology drugs on the market, Amgen stood as the largest and...
View Details
Keywords:
Growth and Development Strategy;
Strategic Planning;
Success;
Risk and Uncertainty;
Pharmaceutical Industry
Nohria, Nitin. "Amgen, Inc.: Planning the Unplannable." Harvard Business School Case 492-052, March 1992.
- Web
Application Process - MBA
application that is true to you and your journey. Joint Degree Programs Applications for both Harvard Business School and the partnering Harvard graduate school must be submitted as explained on these overview pages: MS/MBA Engineering MS/MBA View Details
- July–August 2021
- Article
Lowering the Bar? External Conditions, Opportunity Costs, and High-Tech Startup Outcomes
By: Annamaria Conti and Maria P. Roche
We assess the heterogeneous impact of economic downturns on individuals’ decisions to bring high-technology ideas to the market in the form of new ventures. We thereby examine how worsening labor market conditions influence individuals’ opportunity costs of starting...
View Details
Keywords:
Necessity Entrepreneurship;
Economic Conditions;
Recessions;
High-tech Startups;
Opportunity Costs;
Entrepreneurship;
Economic Slowdown and Stagnation;
Business Startups;
Information Technology;
Performance;
Labor
Conti, Annamaria, and Maria P. Roche. "Lowering the Bar? External Conditions, Opportunity Costs, and High-Tech Startup Outcomes." Organization Science 32, no. 4 (July–August 2021): 965–986.
- April 2002
- Case
In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen
By: Juan Enriquez-Cabot, Gary P. Pisano and Gaye Bok
Biogen is a successful biotech company facing a critical juncture. CEO John Mullen ponders how technological changes introduced into the research function will shape larger corporate decisions. This world in which biotechnology companies operated had changed...
View Details
Keywords:
Change;
Decisions;
Product Development;
Research and Development;
Expansion;
Technology;
Biotechnology Industry
Enriquez-Cabot, Juan, Gary P. Pisano, and Gaye Bok. "In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen." Harvard Business School Case 602-122, April 2002.
- Web
Admissions - MBA
04 Sep 2024 Round 1 Apply Upcoming Events Jun25 25 Jun 2024 MS/MBA Virtual Chat with Alumni Hear directly from current MS/MBA Engineering Sciences and MS/MBA Biotechnology alumni and students regarding their experience. Students and...
View Details
- 15 Sep 2010
- Working Paper Summaries
From Bench to Board: Gender Differences in University Scientists’ Participation in Commercial Science
- April 2009
- Case
GSK's Acquisition of Sirtris: Independence or Integration?
By: Toby E. Stuart and James Weber
An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science....
View Details
Keywords:
Mergers and Acquisitions;
Resource Allocation;
Organizational Change and Adaptation;
Organizational Culture;
Organizational Structure;
Research and Development;
Science-Based Business;
Integration
Stuart, Toby E., and James Weber. "GSK's Acquisition of Sirtris: Independence or Integration?" Harvard Business School Case 809-026, April 2009.
- October 2012
- Case
GSK's Acquisition of Sirtris: Independence or Integration? (Abridged)
By: Toby Stuart and James Weber
An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science....
View Details
Keywords:
Mergers and Acquisitions;
Resource Allocation;
Organizational Change and Adaptation;
Organizational Culture;
Organizational Structure;
Research and Development;
Science-Based Business;
Integration
Stuart, Toby, and James Weber. "GSK's Acquisition of Sirtris: Independence or Integration? (Abridged)." Harvard Business School Case 813-028, October 2012.
- 2008
- Chapter
The Evidence Does Not Speak for Itself: Expert Witnesses and the Organization of DNA-Typing Companies
By: Arthur A. Daemmrich
During the past 15 years, new biotechnology companies have promoted DNA typing as a sophisticated criminal and paternity identification technique. Private testing laboratories produce results that link individuals with crime scenes and fathers to their children....
View Details
- Web
FAQs - MBA
MS/MBA Biotechnology: Life Sciences FAQs Why did Harvard create this program? What is the mission? As the field of biotechnology continues to grow, so too does the need for business leaders who speak science, and scientists who are...
View Details
- January 2011 (Revised July 2012)
- Case
Arcadia Biosciences: Seeds of Change (Abridged)
By: Arthur A. Daemmrich
Arcadia Biosciences is seeking to introduce genetically modified rice to China that will lower farmers' costs and generate environmental benefits through reduced greenhouse gas emissions. The case describes challenges facing this small agricultural biotechnology...
View Details
Keywords:
Plant-Based Agribusiness;
Intellectual Property;
Genetics;
Environmental Sustainability;
Science-Based Business;
Climate Change;
Biotechnology Industry;
Biotechnology Industry;
China
Daemmrich, Arthur A. "Arcadia Biosciences: Seeds of Change (Abridged)." Harvard Business School Case 711-050, January 2011. (Revised July 2012.)
- Web
MBA Key Dates & Calendar - MBA
MBA Key Dates & Calendar MBA Key Dates & Calendar Verification of Attendance MBA Key Dates & Calendar Some important dates in the MBA Program during the 2024-2025 Academic Year: 2024 1 AUG MS/MBA: Engineering and MS/MBA: Biotechnology RC...
View Details
- Person Page
Press / Media
By: Gary P. Pisano
Thought Leader: Gary Pisano
by Amy Bernstein, strategy+business, Summer 2007
A leading student of the biotech business describes the problems holding the industry back, and how it can overcome... View Details